Primary Treatment of Chronic Pulmonary Aspergillosis with Weekly Liposomal Amphotericin B: A Case Report from Uganda

Overview

Journal Med Mycol Case Rep

Publisher Elsevier

Date 2024 Sep 24

PMID 39314643

Authors

Winnie Kibone

Felix Bongomin

David W Denning

David B Meya

Affiliations

Soon will be listed here.

Abstract

Chronic pulmonary aspergillosis (CPA) treatment in Africa remains unexplored. We present a 23-year-old Ugandan male, previously treated thrice for pulmonary tuberculosis, developing CPA. Imaging showed lung fibrosis, bronchiectasis, and a fungal ball. He received weekly 600mg (10mg/kg) of liposomal amphotericin B for six weeks, leading to marked clinical improvement. Weekly liposomal amphotericin B may be a viable treatment option for CPA in resource-limited settings.

References

Denning D . Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024; 24(7):e428-e438. DOI: 10.1016/S1473-3099(23)00692-8. View

Bongomin F, Harris C, Hayes G, Kosmidis C, Denning D . Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One. 2018; 13(4):e0193732. PMC: 5892866. DOI: 10.1371/journal.pone.0193732. View

Faustino C, Pinheiro L . Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics. 2020; 12(1). PMC: 7023008. DOI: 10.3390/pharmaceutics12010029. View

Chen J, Chang Y, Luh S, Lee J, Lee Y . Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax. 1997; 52(9):810-3. PMC: 1758650. DOI: 10.1136/thx.52.9.810. View

Bongomin F, Asio L, Baluku J, Kwizera R, Denning D . Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist. J Fungi (Basel). 2020; 6(2). PMC: 7345130. DOI: 10.3390/jof6020075. View

Isnard M, Hullo E, Robert Y, Piolat C, Durand C, Lantuejoul S . [Post-traumatic pulmonary aspergilloma]. Rev Mal Respir. 2018; 35(3):342-346. DOI: 10.1016/j.rmr.2017.05.005. View

Bekersky I, Fielding R, Dressler D, Lee J, Buell D, Walsh T . Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002; 46(3):828-33. PMC: 127462. DOI: 10.1128/AAC.46.3.828-833.2002. View

Newton P, Harris C, Morris J, Denning D . Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis. J Infect. 2016; 73(5):485-495. DOI: 10.1016/j.jinf.2016.06.001. View

Bongomin F, Asio L, Olum R, Denning D . Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses. 2020; 63(9):921-927. DOI: 10.1111/myc.13131. View

10.

Fujita M, Hirano R, Matsumoto T, Watanabe K . [Pilot study of intermittent administration of liposomal amphotericin B for chronic pulmonary aspergillosis]. Jpn J Antibiot. 2014; 67(3):205-10. View

11.

Baradkar V, Mathur M, Kumar S . Uncommon presentation of pulmonary aspergilloma. Indian J Med Microbiol. 2009; 27(3):270-2. DOI: 10.4103/0255-0857.53216. View

12.

Bongomin F, Kwizera R, Namusobya M, van Rhijn N, Andia-Biraro I, Kirenga B . Re-estimation of the burden of serious fungal diseases in Uganda. Ther Adv Infect Dis. 2024; 11:20499361241228345. PMC: 10848809. DOI: 10.1177/20499361241228345. View

13.

Denning D, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S . Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2015; 47(1):45-68. DOI: 10.1183/13993003.00583-2015. View